Compound ID | 845
SB-268091
Class: Pleuromutilin
| Spectrum of activity: | Gram-negative |
| Details of activity: | Protein synthesis inhibitor; potent against S. aureus, S. epidermidis and S. pyrogenes. Reviewed for topical treatment for skin disorders and for respiratory tract infections. |
| Institute where first reported: | SmithKline Beecham (GSK, US) |
| Year first mentioned: | 1999 |
| Development status: | Inactive |
| Reason Dropped: | Pleuramutilins had some toxicities but were used in animals for many years befor GSK developed the topical treatment retapamulin and now Nabriva is developing lefamulin. This could be due to tosicity or due to poor pharmokinetics (LS) |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.